Rigel Pharmaceuticals Inc splits its revenue into 7 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Gross Product at $310.0 million, 105% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
288
|
294
|
179
|
117
|
120
|
149
|
109
|
59
|
45
|
| Gross Product |
—
|
310
+47.7%
share 105.3%
|
210
+42.7%
share 117.1%
|
147
+35.5%
share 125.8%
|
109
share 90.3%
|
—
|
76
+44.1%
share 70.4%
|
53
share 89.5%
|
—
|
| Release Of Share Cost Liability |
—
|
40
share 13.6%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Royalty Delivery Of Drug Supplies And Others |
—
|
19
-6.5%
share 6.5%
|
20
+78.5%
share 11.4%
|
11
share 9.8%
|
—
|
3
-26.2%
share 2.2%
|
4
+238.4%
share 4.1%
|
1
share 2.2%
|
—
|
| License |
—
|
—
|
14
share 7.8%
|
—
|
8
-88.8%
share 6.6%
|
71
+74.8%
share 47.3%
|
40
+364.1%
share 37.2%
|
9
share 14.7%
|
—
|
| Development Milestones |
—
|
3
share 1.0%
|
—
|
0
-99.7%
share 0.1%
|
25
+1233.3%
share 20.8%
|
2
-10.7%
share 1.3%
|
2
-61.8%
share 1.9%
|
6
share 9.3%
|
—
|
| Government Contract |
—
|
0
share 0.1%
|
—
|
1
-75.6%
share 0.9%
|
4
-57.1%
share 3.7%
|
10
share 7.0%
|
—
|
—
|
—
|
| Discounts And Allowances |
—
|
-78
-19.9%
share -26.5%
|
-65
-52.0%
share -36.3%
|
-43
-34.5%
share -36.6%
|
-32
-75.0%
share -26.5%
|
-18
-23.0%
share -12.2%
|
-15
-58.7%
share -13.6%
|
-9
share -15.7%
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RIGL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1034842
- Former names
- RIGEL PHARMACEUTICALS INC (until Nov 5, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.